In a proof-of-concept clinical study, the ALT-TEN trial, twelve patients with hematological malignancies undergoing haplo-HSCT were given IL-10-anergized donor T cells (IL10-DLI) containing Tr1 cells to support immune reconstitution in the absence of severe GvHD (32). The gene discussed is IL10; the disease is graft versus host disease.